MedPath

Clinical Pharmacology Study of Z-206 - Study on Drug Concentration in Mucous Membrane of Z-206 in Healthy Male Adults

Phase 2
Conditions
lcerative Colitis
Registration Number
JPRN-UMIN000000678
Lead Sponsor
Zeria Pharmaceutical Co., LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects with hypersensitivity to drugs, drug dependency, or alcohol dependency or history of such 2)Subjects currently suffering from impediments of the digestive organs, disorders of the liver, renal disorders, hematological disorders, circulatory system diseases, mental or nervous disorders, etc., which are considered to be inappropriate for the participation in trial or history of such 3)Subjects with HBs antigen, HCV antibody, HIV antigen antibody, and positive syphilis serum test 4)Subjects taking a drug(s) within 1 week of the administration of the trial drug 5)Subjects receiving administration of any trial drug within 4 months prior to the trial drug administration 6)Subjects who received whole blood collection of 200 mL within 1 month before the trial drug administration or component blood collection within 2 weeks or blood collection of 400 mL or more (such as blood donation) within 3 months 7)Others, subjects judged by the principal investigator or co-investigators to be inappropriate for participation in this drug trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The drug concentration in the mucous membrane of the large intestines
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath